Periodic Benefit-Risk Evaluation Report (PBRER)

Target entity: Periodic Benefit-Risk Evaluation Report (PBRER)
Context triple: [ICH E2C(R2), fullName, Periodic Benefit-Risk Evaluation Report (PBRER)]

• A. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
  The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
• B. FDA Risk Evaluation and Mitigation Strategies authority
  The FDA Risk Evaluation and Mitigation Strategies authority is the U.S. Food and Drug Administration’s power to require special safety measures and monitoring programs for certain high-risk prescription drugs to ensure their benefits outweigh their risks.
• C. Pharmacovigilance Risk Assessment Committee
  The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of human medicines and advising on risk management measures in the European Union.
• D. FDA Adverse Event Reporting System
  The FDA Adverse Event Reporting System is a U.S. Food and Drug Administration database that collects and analyzes reports of adverse events and medication errors associated with drugs and therapeutic biologic products.
• E. Behavioral Risk Factor Surveillance System
  The Behavioral Risk Factor Surveillance System is a large, ongoing U.S. health-related telephone survey system that collects data on health behaviors, chronic conditions, and preventive service use among adults.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: Periodic Benefit-Risk Evaluation Report (PBRER)
Target entity description: The Periodic Benefit-Risk Evaluation Report (PBRER) is a standardized pharmacovigilance document used by pharmaceutical companies to periodically assess and summarize the evolving benefits and risks of a medicinal product throughout its lifecycle.

• A. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
  The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
• B. FDA Risk Evaluation and Mitigation Strategies authority
  The FDA Risk Evaluation and Mitigation Strategies authority is the U.S. Food and Drug Administration’s power to require special safety measures and monitoring programs for certain high-risk prescription drugs to ensure their benefits outweigh their risks.
• C. Pharmacovigilance Risk Assessment Committee
  The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of human medicines and advising on risk management measures in the European Union.
• D. FDA Adverse Event Reporting System
  The FDA Adverse Event Reporting System is a U.S. Food and Drug Administration database that collects and analyzes reports of adverse events and medication errors associated with drugs and therapeutic biologic products.
• E. Behavioral Risk Factor Surveillance System
  The Behavioral Risk Factor Surveillance System is a large, ongoing U.S. health-related telephone survey system that collects data on health behaviors, chronic conditions, and preventive service use among adults.
• F. None of above. chosen